Eritrea

in page functions
[French]
Eritrea
Total population (2019) 5,753,915
Birth cohort (2019) 177,092
Surviving Infants (surviving to 1 year per year, 2019) 101,159
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 34/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 47/1000
World Bank Index, IDA (2015) 1.94
Gross Nation Income (per capita US$, 2011) 480
No. of districts/territories (2018) 58
Download this page as a PDF factsheet

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Eritrea

Type of support

Approvals

2001-2023 (US$)
(17 Sep 2019)

Commitments

2001-2023 (US$)
(17 Sep 2019)

Disbursements

2000-2019 (US$)
(17 Sep 2019)

% Disbursed

(17 Sep 2019)
 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Total $35,199,454 $46,569,308 $36,507,810
Cold Chain Equipment Optimisation Platform (CCEOP) $970,534 $970,534 $967,137 100%
Health system strengthening (HSS 1) $2,778,000 $2,778,000 $2,778,000 100%
Health system strengthening (HSS 2) $4,800,148 $12,000,002 $4,609,522 96%
Immunisation services support (ISS) $436,540 $436,540 $436,540 100%
Injection Safety Devices (NVS) $263,500 $287,000 $310,930 118%
Injection safety support (INS) $148,029 $148,029 $148,029 100%
IPV (NVS) $508,567 $508,567 $525,975 103%
Measles (NVS) $239,197 $239,197 $248,024 104%
Meningitis A - campaign (NVS) $2,192,500 $2,192,500 $2,310,016 105%
Meningitis A - operational costs (OPC) $1,825,484 $1,825,484 $1,825,484 100%
MR 1st and 2nd dose (NVS) $129,000 $355,000 $138,296 107%
MR-Catch-up campaign (NVS) $1,180,500 $1,180,500 $1,225,093 104%
MR-Catch-up campaign op.costs (OPC) $1,015,300 $1,015,300 $1,015,300 100%
Penta (NVS) $7,485,380 $8,160,880 $8,010,630 107%
Pneumo (NVS) $5,761,389 $7,970,389 $6,565,405 114%
Product Switch Grant (PSG) $31,841 $31,841 $31,841 100%
Rotavirus (NVS) $2,360,908 $3,396,908 $2,288,951 97%
Tetra DTP-HepB (NVS) $2,312,677 $2,312,677 $2,312,677 100%
Vaccine Introduction Grant (VIG) $759,960 $759,960 $759,960 100%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Eritrea DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2018)

Grade of confidence

N/A
DTP3 - Official country estimates (2018) 95%
M:F sex ratio at birth (2019) 1.05
Household survey: DTP3 coverage for male (2001) 81.60%
Household survey: DTP3 coverage for female (2001) 84.20%
Household survey: Last DTP3 survey (2007) 98%
% districts achieving > 80% DTP3 coverage (2018) 47%
% districts achieving < 50% DTP3 coverage (2018) 12%
MCV WHO/UNICEF estimates (2018) 99%

Breakdown of support

Non-vaccine support Vaccine support
34% 66%
$12,571,813 $23,935,997

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Eritrea

22 February 2016

Gavi item

Meningitis A nearly eliminated in Africa through vaccination

Joint press release first published by WHO and PATH, joint founders of the Meningitis Vaccine Project.

15 March 2013

Rt Hon Stephen O’Brien MP in Rwanda

Why I am a Red Nose Day supporter

I firmly believe that it is in the British character to try to help those whose lives are blighted by disease, poverty and violence. Red Nose Day, supported by Comic Relief, gives millions of people across the country the opportunity to do just that.

03 December 2012

MenAfriVac

100 millionth person receives lifesaving meningitis vaccine

A revolutionary meningitis vaccine will reach the 100 millionth person this week in a region of Africa that has been plagued by deadly epidemics for more than a century. The milestone will take place in northern Nigeria, part of Africa’s “meningitis belt’, where the country is conducting its second seasonal immunisation campaign against the disease.

Useful links

View all sources for data in this page

Disclaimer: the boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of Gavi, the Vaccine Alliance concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

close icon

modal window here